VASCO study: A population-based prospective cohort study on vaccine effectiveness of COVID-19 vaccines in the Netherlands

Phase 4

Recruiting

• Conditions: corona; COVID-19; SARS-CoV-2 infection; 10047438

• Registration Number: NL-OMON55915
• Lead Sponsor: Ministerie van Volksgezondheid, Welzijn en Sport (VWS)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 50000

Inclusion Criteria

- Community dwelling adult between 18-84 years
- Informed consent provided
- Be able to read, understand and write Dutch

Exclusion Criteria

- Not able or willing to understand and sign the informed consent
- Not able to fill out a digital (app) questionnaire
- Persons living in an institution (e.g. elderly care home, nursing home)

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is symptomatic SARS-CoV-2 infection, determined by a<br /><br>positive PCR or antigen test in combination with COVID-19 related symptoms.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary endpoints are SARS-CoV-2 infections by disease severity and<br /><br>unsolicited adverse events of special interest following vaccination.</p><br>